Patent ID: 9216228
Filing Date: 2015-12-22
Classification: A61K,A61P,B82Y

Abstract:
1. A prodrug, comprising (i) at least one pharmaceutically and/or diagnostically active compound, (ii) at least one receptor and/or antigen targeting moiety, wherein the receptor and/or antigen targeting moiety is a peptide derivative comprising the sequence (Pyr)-His-Trp-Ser-Tyr-Lys-Leu-Arg-Pro-Gly-NH2 (SEQ ID NO: 1), (iii) at least one cleavable linker, and (iv) a protein-binding moiety which binds in situ to serum proteins following administration of the prodrug, wherein the at least one pharmaceutically and/or diagnostically active compound is bound to the at least one cleavable linker, wherein the at least one cleavable linker, the protein binding moiety, and the at least one receptor and/or antigen targeting moiety are joined to form a branched structure; and wherein the protein-binding moiety is selected from the group consisting of a maleinimide group, a halogenacetamide group, a halogenacetate group, a pyridylthio group, a vinylcarbonyl group, an aziridin group, a disulfide group, a substituted or unsubstituted acetylene group, and a hydroxysuccinimide ester group.